British National Formulary 71

This Medical Association and Royal Pharmaceutical Society of Great Britain app-book, BNF 71, is developed by Medhand Mobile Libraries. Improve your performance with relevant, valid material which is accessed quickly and with minimal effort in the palm of your hand using Medhands patented technology.

Important: This is a downloaded, offline app. The application is a single edition only; to stay updated it is recommended to purchase the forthcoming editions as they are revised twice yearly.

Functions include:

• A powerful search
• Bookmarks, History and Highlighting
• Complete set of medical calculators; Body Mass Index, Peak Expiratory Flows, Dehydration Correction Calculator and more
• Notes and picture notes

Content of the BNF reflects current best practice as well as legal and professional guidelines relating to the uses of medicines. The resource includes:

• Guidance on the drug management of common conditions
• Details of medicines prescribed within the UK with special reference to their uses, cautions, contra-indications, side-effects, doses and relative costs. This allows treatment to be tailored to the individual needs of each patient.
• Guidance on prescribing, monitoring, dispensing and adminstering medicines.

The content has been revised and revalidated to reflect changes in product availability, emerging safety concerns and shifts in clinical practice.

Some of the significant content updates in this edition include:

• New safety information, including:
o very low risk of subacute cutaneous lupus erythematosus with proton pump inhibitors
o risk of severe bradycardia and heart block when hepatitis C drugs taken with amiodarone hydrochloride
o risk of diabetic ketoacidosis with sodium glucose co-transporter 2 (SGLT2) inhibitors
o increased reports of eye irritation since reformulation of latanoprost (Xalatan®)
• Updated advice for further measures to minimise risk of osteonecrosis of the jaw associated with use of denosumab and intravenous bisphosphonates
• Updated safety information on risk factors for uterine perforation associated with the use of intra-uterine contraception (intra-uterine contraceptive devices (copper) and levonorgestrel)
• Inclusion of monitoring recommendations for risks of cardiac failure with crizotinib
• Updates to immunisation schedule (Summer 2015): meningococcal group B vaccine, meningococcal groups A, C, W135 and Y vaccine, and influenza vaccine added
• Addition of new preparations including Otezla® (apremilast), Kengrexal® (cangrelor), Velphoro® (sucroferricoxyhydroxide), and more
• Significant dose changes including avanafil, colistimethate sodium (Promixin®), oseltamivir, and more

Authors: Joint Formulary Committee

________________________________________

MedHand Mobile Libraries offers a SUBSCRIPTION FREE application without edition upgrade. Offering most trusted and well recognized medical guidelines provided by excellent publishers like Pharmaceutical Press, Oxford University Press, McGraw-Hill, Wiley, Elsevier and more.